Agex Therapeutics Stock Fundamentals
| AGEDelisted Stock | USD 0.74 0.01 1.37% |
AgeX Therapeutics fundamentals help investors to digest information that contributes to AgeX Therapeutics' financial success or failures. It also enables traders to predict the movement of AgeX Stock. The fundamental analysis module provides a way to measure AgeX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AgeX Therapeutics stock.
AgeX |
AgeX Therapeutics Company Shares Owned By Insiders Analysis
AgeX Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current AgeX Therapeutics Shares Owned By Insiders | 75.73 % |
Most of AgeX Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AgeX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 75% of AgeX Therapeutics are shares owned by insiders. This is 398.88% higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
AgeX Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AgeX Therapeutics's current stock value. Our valuation model uses many indicators to compare AgeX Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AgeX Therapeutics competition to find correlations between indicators driving AgeX Therapeutics's intrinsic value. More Info.AgeX Therapeutics is rated below average in return on asset category among its peers. It is rated below average in operating margin category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value AgeX Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.AgeX Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AgeX Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AgeX Therapeutics could also be used in its relative valuation, which is a method of valuing AgeX Therapeutics by comparing valuation metrics of similar companies.AgeX Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
AgeX Fundamentals
| Return On Asset | -0.82 | |||
| Operating Margin | (63.57) % | |||
| Current Valuation | 33.33 M | |||
| Shares Outstanding | 2.5 M | |||
| Shares Owned By Insiders | 75.73 % | |||
| Shares Owned By Institutions | 5.64 % | |||
| Number Of Shares Shorted | 4.47 K | |||
| Price To Earning | (5.95) X | |||
| Price To Book | 12.96 X | |||
| Price To Sales | 221.90 X | |||
| Revenue | 142 K | |||
| Gross Profit | 125 K | |||
| EBITDA | (9.83 M) | |||
| Net Income | (14.8 M) | |||
| Cash And Equivalents | 645 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 4.37 M | |||
| Debt To Equity | 0.75 % | |||
| Current Ratio | 0.19 X | |||
| Book Value Per Share | 5.07 X | |||
| Cash Flow From Operations | (7.8 M) | |||
| Short Ratio | 3.88 X | |||
| Earnings Per Share | (13.36) X | |||
| Beta | 1.19 | |||
| Market Capitalization | 31.51 M | |||
| Total Asset | 11.96 M | |||
| Retained Earnings | (131.01 M) | |||
| Working Capital | (5.16 M) | |||
| Current Asset | 5.06 M | |||
| Current Liabilities | 5.17 M | |||
| Z Score | -14.21 | |||
| Net Asset | 11.96 M |
About AgeX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AgeX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AgeX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AgeX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California. Agex Therapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 5 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in AgeX Stock
If you are still planning to invest in AgeX Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AgeX Therapeutics' history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |